The reduction in proliferation, blood vessel number, tumor‐fenestrated collagen, and nuclear YAP/TAZ was consistent with agrin loss in PDX#20 in response to the combination therapy, while no major differences amongst the non‐responsive PDX#18 tumors were observed (Figure 7F; Figure S10I, Supporting Information). Here, AGRN is linked to neoplasm.